Alnylam Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $19.26BP/E 7.5Yield –
Alnylam Pharmaceuticals Alnylam Cumulative Total Shareholder Return Value of by Year
Alnylam Cumulative Total Shareholder Return (TSR) Value of Initial $100 Investment ($) ($)
Alnylam Pharmaceuticals Alnylam Cumulative Total Shareholder Return Value of: $306 in FY2025, up 69.0% from a year earlier.
Where the FY2025 figure comes from
“|| 2025 | 14,867,600 | 77,428,521 | 6,582,418 | 19,817,949 | 305.96 | 124.75 | 313,747 | 2,986,549”
Source: Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alnylam Cumulative Total Shareholder Return (TSR) Value of Initial $100 Investment ($) ($) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 306 | +69.0% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2024 | Dec 31, 2024 | 181 | +22.9% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2023 | Dec 31, 2023 | 147 | -19.5% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2022 | Dec 31, 2022 | 183 | +40.1% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2021 | Dec 31, 2021 | 130 | +15.6% | Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗ |
| FY2020 | Dec 31, 2020 | 113 | – | Alnylam Form DEF 14A (2025 Proxy Statement (DEF 14A), filed 2025-03-24) ↗ |
Cite this data
StockData. (2026). Alnylam Pharmaceuticals Alnylam Cumulative Total Shareholder Return Value of ($), annual FY2020–FY2025 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/proxy-tsr-100
See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.
See a number that looks wrong?